

Second Quarter Fiscal Year 2016 Financial Report (Unaudited Statements)

Cone Health is an integrated health care delivery system based in Greensboro, NC serving Greensboro and the surrounding counties through a system of hospitals, ambulatory care centers, physician offices and other related health care facilities. The primary and secondary service areas have almost one million residents for which Cone maintains a dominant market presence.

OPERATIONS

- 6 Hospitals 1,254 licensed beds
- 3 Ambulatory Surgery Centers
- 2 Nursing Homes 221 beds
- 1 Continuing Care Retirement Community
- 3 Ambulatory Care campuses
- 149+ Outpatient facilities
- 1,400+ Medical Staff, 500 employed

Over 12,000 employees

Triad Healthcare Network – clinically integrated with over 875 affiliated physicians

40,000 member Medicare ACO

6,000 member Medicare

For the six months ended March 31, 2016 the Health System's consolidated operating income was \$16.7M and a margin of 2.0% compared to operating income of \$27.8M and a margin of 3.7% for the same period ended March 31, 2015. Excess of revenues over expenses were \$24.1M and an excess margin of 2.9% compared to \$21.3M and 2.8% for the same period in fiscal year 2015.

The first six months of fiscal year 2016 continued the trend of higher outpatient volumes from fiscal year 2015, as net patient revenue increased 7.5% to \$780.9M. Compared to fiscal year 2015, inpatient volume decreased slightly by 1.4% to 15,176 for the year while acute length of stay decreased by 0.02 to 4.17 days driven by an increase in case mix from 1.54 to 1.61. Salaries and wages increased in line with patient volume, but benefits increased by 12.5% representing a higher cost of employee health and other employee benefits. Depreciation expense increased 12.9% to \$51.9M reflecting continued investment in facilities and information technology.

Supplies expense increased 14.2% principally driven by supplies for intensive inpatient surgeries and drug expenses for cancer treatments as well as employee and specialty pharmacies.

Non-operating income (other income) improved by \$14.2 million to positive \$7.8 million reflecting improved realized gains on investments.

| Summary Statement of Operations (\$000) | | | | |
|---|----------|-----------|--|--|
| First Quarter ended March 31, 2016 | YTD | Prior YTD | | |
| Operating income | \$16,715 | \$27,762 | | |
| Operating Margin % | 2.0% | 3.7% | | |
| Operating EBIDA | \$73,864 | \$78,988 | | |
| Operating EBIDA Margin % | 8.9% | 10.5% | | |
| Excess of revenue over expenses | \$24,146 | \$21,265 | | |
| Excess Margin % | 2.9% | 2.8% | | |
| Change in Net Assets | \$11,733 | \$20,928 | | |

Surgical procedures increased slightly to 21,009 fiscal year to date, an increase of 0.4% over last fiscal year. Emergency department visits were up 4.0% attributable to seasonal flu and respiratory cases. Physician services were up sharply, driven by a number of factors including volume at the Cancer Center, as well as an increased number of affiliated physicians.

| Operating Statis | tics Fi | scal Year to date 201 | 16 |
|---------------------------|--------------|-----------------------|------------|
| | Current Year | Prior year | % Variance |
| Surgical Procedures | 21,009 | 20,932 | 0.4% |
| Deliveries | 3,676 | 3,713 | -1.0% |
| ED Visits | 182,746 | 175,729 | 4.0% |
| Outpatient Visits | 357,900 | 341,089 | 4.9% |
| Physician Services | | | |
| Office Visits | 342,056 | 330,832 | 3.4% |
| Physician Hospital Visits | 105,775 | 102,683 | 3.0% |
| Procedures | 222,450 | 203,998 | 9.0% |

Although inpatient activity for the system was marginally below prior year, despite increased acuity and a higher average daily census.

| Hospital Statistics | Fiscal Year to date 2016 | | | |
|-----------------------------------|--------------------------|------------|------------|--|
| | <u>Actual</u> | Prior year | % Variance | |
| Beds in Service | 1,144 | 1,154 | -0.9% | |
| Number of Inpatients (Discharges) | 30,672 | 31,149 | -1.5% | |
| Average Length of Stay | 4.25 | 4.29 | 0.9% | |
| Average Daily Acute Census | 1,061 | 1,086 | -2.4% | |
| Extended Care Census | 298 | 273 | 9.2% | |
| Long Term Care Census | 85.8 | 81.4 | 5.4% | |

Balance Sheet liquidity ratios softened in the first six months of the year driven by a small loss in long term investments, investments in capital projects and increases in patient receivables. Unrestricted cash and investments decreased by \$7.1M during the first six months of the fiscal year. The fiscal year-to-date return on the system investment portfolio was a loss of 0.1% as the portfolio value orientation and low equity exposure hurt performance. The decline in day's cash on hand was principally driven by strong growth in top line revenue and expenses.

Balance Sheet Summary of Key Metrics and Ratios as of

| | YTD | Prior Qtr. | Change | Prior FYE |
|---------------------------------------|-----------|------------|----------|-----------|
| Cash and long-term investment (\$000) | \$892,347 | \$878,913 | \$13,434 | \$899,401 |
| Days cash on hand | 215 | 219 | -4 | 235 |
| Days in A/R | 51 | 48 | 3 | 49 |
| Cash to debt | 180% | 184% | -4% | 186% |
| Debt to capitalization | 25.5% | 24.7% | 1% | 25.2% |
| Annual debt service coverage ratio | 6.81 | 7.52 | -0.71 | 6.15 |

Debt Summary As of March 31, 2016

The following table shows debt under the Cone Master Trust Indenture, and excludes smaller direct loans and leases. Cone's debt is rated AA/Stable by both Standard & Poor's and FITCH Investors Service.

| Outstanding Debt Series as of March 31, 2016 Principal(\$) | | | | | |
|--|-------------|-------------|-------|--------------|----------------------|
| Current | | | | | |
| | Original | Outstanding | Rate | Maturity(FY) | Interest Mode |
| 2001A | 42,600,000 | 42,600,000 | 0.89% | 2019 | Weekly VRDB |
| 2001B | 42,600,000 | 42,600,000 | 0.90% | 2019 | Daily VRDB |
| 2004A | 47,500,000 | 47,500,000 | 0.98% | 2017 | Weekly VRDB |
| 2011A | 60,170,000 | 42,185,000 | 4.42% | 2023 | Fixed Rate |
| 2011B | 47,980,000 | 47,885,000 | 0.75% | 2036 | Windows Mode |
| 2011C & D | 100,000,000 | 97,500,000 | 0.98% | 2021 | Direct Placement |
| 2013A, B & C | 130,185,000 | 119,250,000 | 2.82% | 2024 | Direct Placement |
| | 471,035,000 | 439,520,000 | | | |

Rates include all related fees including remarketing, credit support and trustee.

VRDB maturities are the renewal date of credit support.

Direct placement maturities are the renewal date of rate agreements.

The 2001 A&B bonds are swapped to maturity at a rate of 3.43%.

The 2011B bonds are swapped to maturity at a rate of 2.097%.

The 2004A and 2011B bonds are supported with Cone Health's liquidity that totaled \$765 million at March 31, 2016, not including funds of the Cone Foundation and Impact Alamance Foundation. Two lines of credit totaling \$97.5 million are also available to support outstanding indebtedness. The availability of Cone's liquidity is shown in the following table.

| self-supported bond exposure (excluding Foundation assets) | | | | | |
|--|-------------------------|--------|---------------------|-------------|--|
| | | | Funds Availabil | ity | |
| <u>Type</u> | Market Value (Millions) | 1-Day | <u>Under 1-Week</u> | Over 1-Week | |
| Deposits at Banks | \$40.5 | \$40.5 | ¢112.4 | ¢17.0 | |
| Bond Funds | \$200.5 | \$69.3 | \$113.4 | \$17.8 | |

Cons Health Lieuviller As of March 21, 2016 available to support data represents and

Equity Funds \$205.3 \$58.8 \$146.5 Other Funds \$319.3 \$29.8 \$12.3 \$277.2 \$765.6 \$184.5 \$441.5 **Total Liquid Assets** \$139.6 Bank Lines of Credit \$97.5 \$97.5 **Total Liquidity** \$863.1 \$237.1 \$184.5 \$441.5

\$47.5 million in bank lines of credit are only available to support a failed remarketing of the 2004A bonds. The remaining \$50 million line is available for general working capital purposes. In October, subsequent to fiscal year end, Cone entered into an additional line of credit in the amount of \$50 million to provide liquidity in the event that the adoption of ICD-10 coding on October 1st resulted in a temporary slowdown in receivables collection and decrease in available cash.

The values of investments in the above chart are market values for Cone Health assets, not including foundation assets. The market values are higher than financial statement values because certain investments in the financial statements are carried at cost, not market value.

Contact Information

John Miller CIO and Treasurer John.Miller@ConeHealth.com Andy Barrow VP Finance

Andy.Barrow@ConeHealth.com

Ratio Methodology

Long Term Debt Service Coverage Ratio

Excess of Revenues + Depreciation+ Interest / Interest + Principal

For interim periods, Excess of Revenues and Depreciation are annualized, Interest and Principal are estimated for the full year. Interest Expense includes remarketing, credit support, trustee fees and other related expenses.

Days Cash on Hand

Unrestricted Cash and Investments / Operating Expense less Depreciation

For interim periods, the calculation is based on actual number of days in the period.

Debt to Capital Ratio

Short and Long Term Debt + Leases / Total Capitalization

Total Capitalization is Short and Long Term Debt + Leases + Unrestricted Net Assets

Max Annual Debt Service Coverage Ratio

Same as the Long Term Debt Service Coverage Ratio, except the interest and principal is the largest scheduled debt service amount estimated for each future year. Variable rate debt is estimated using the 10 year average of SIFMA plus related expenses.

Cash to Debt Ratio

Unrestricted Cash and Investments / Short and Long Term Debt + Leases

Cone Health Consolidated Balance Sheets

| Assets | March 31, 2016 | Audited September 30, 2015 | Liabilities and Net Assets | March 31, 2016 | Audited September 30, 2015 |
|------------------------------------|-----------------|-------------------------------|--|-----------------|-------------------------------|
| Current Assets | | | Current Liabilities | | |
| Cash | \$ 51,733,195 | \$ 27,152,128 | Accrued Payroll | \$ 72,983,626 | \$ 75,548,269 |
| Short-term investments | 25,056,701 | 39,501,735 | Accounts Payable | 51,432,122 | 57,151,214 |
| Patient Receivables (net) (Note 1) | 219,081,705 | 205,578,977 | PAL & Retirement | 40,831,198 | 31,472,387 |
| Other Receivables | 46,292,379 | 21,610,735 | Medical Claims IBNR (Note 5) | 3,215,649 | - |
| Inventories | 28,985,297 | 27,639,854 | Bonds Payable (Note 6) | 12,265,000 | 12,459,931 |
| Prepaid Expenses | 12,101,803 | 15,456,292 | Short Term Debt, Line of Credit (Note 6) | 191,341,080 | 181,014,193 |
| Other Current Assets | 4,311,068 | 6,446,312 | Other Current Liabilities | 67,374,657 | 70,281,230 |
| Total Current Assets | 387,562,148 | 343,386,033 | Total Current Liabilities | 439,443,332 | 427,927,224 |
| Plant and Property(net) | | | | | |
| Land and Land Improvements | 100,571,788 | 99,843,954 | Debt and Other Liabilities | | |
| Building and Fixed Equipment | 674.837.768 | 668.063.886 | Bonds Payable (Note 6) | 247,990,000 | 258,310,000 |
| Moveable Equipment | 199,786,529 | 188,161,715 | Long Term Debt (Note 6) | 53,699,479 | 31,001,312 |
| Real Estate | 11,678,427 | 11,773,428 | Capital Lease Obligation | 1,281,620 | 2,012,057 |
| | 986,874,512 | 967,842,983 | Other Non-Current Liabilities | 157,059,988 | 153,595,150 |
| Construction/Equipment In Progress | 56,036,140 | 66,943,611 | Total Liabilities | 899,474,419 | 872,845,743 |
| Total Plant and Property (Note 2) | 1,042,910,652 | 1,034,786,594 | | | |
| Other Non Current Assets | | | Net Assets | | |
| Marketable Securities (Note 3) | 821,342,260 | 837,013,218 | Unrestricted | 1,452,940,332 | 1,442,445,101 |
| Joint Ventures (Note 4) | 51,842,566 | 51,099,203 | Noncontrolling Interest | 8,242,222 | 7,827,080 |
| Investment in Unrelated Parties | 588,024 | 588,024 | Total Unrestrictred Net Assets | 1,461,182,554 | 1,450,272,181 |
| Trustee held bond funds | 1.065.392 | 8.343.685 | | 1,101,10=,001 | 1,100,-1-,101 |
| Subtotal Investments | 874,838,242 | 897,044,130 | | | |
| | | | Temporarily Restricted | 11,642,303 | 12,363,152 |
| Deferred Costs | 3,023,714 | 3,028,945 | Total Restrictred Net Assets | 11,642,303 | 12,363,152 |
| Other Assets | 54,235,182 | 47,506,036 | | | |
| Goodwill | 9,729,338 | 9,729,338 | | | |
| Total Other Non-Current Assets | 66,988,234 | 60,264,319 | | | |
| TOTAL ASSETS | \$2,372,299,276 | \$2,335,481,076 | TOTAL LIAB. AND NET ASSETS | \$2,372,299,276 | \$2,335,481,076 |

Cone Health Consolidated Statements of Operations

| Provision for bad debts (Note 1) Net Patient Service Revenue (Note 2) 780,907,489 728,485,797 7. Other Operating Revenue 33,281,675 25,922,499 28. Premium Revenue (Note 5) 13,115,132 - 0. TOTAL OPERATING REVENUES 827,304,296 752,408,296 9. EXPENSE Salaries and Wages Salaries and Wages Salaries and Wages Fringe Benefits 116,207,559 103,254,398 -12. Purchased Personnel 7,709,285 5,703,203 -35. Medical Claims Expense (Note 5) 159,492,887 139,658,006 -14. Other Operating Expense 149,372,302 136,140,867 -9. Interest Expense 149,372,302 136,140,867 -9. Interest Expense 149,372,302 136,140,867 -9. Interest Expense 149,372,302 150,492,887 150,492,887 150,492,887 150,492,887 150,492,887 150,492,887 150,492,887 150,408,787 -9. Interest Expense 149,372,302 150,492,887 150,408,787 -9. Interest Expense 150,492,887 150,492,887 150,492,887 150,408,787 -9. Interest Expense 149,372,302 150,492,887 150,408,787 -9. Interest Expense 150,492,887 150,492,887 150,408,787 150,408,787 150,408,787 150,408,787 150,408,788,887 150,408,787 150 | | | YEAF | R-TO-DATE | |
|--|--|----|----------------|-------------|-----------|
| Patient Service Revenue (net of contractual allowances and discounts) | | | | | |
| Patient Service Revenue (net of contractual allowances and discounts) | REVENUE | | | | |
| Section Sect | | | | | |
| Provision for bad debts (Note 1) | , | \$ | 847 863 495 \$ | 788 700 384 | 7.50% |
| Net Patient Service Revenue (Note 2) 780,907,489 726,485,797 7.5 | , | Ψ | , , , | | 7.62% |
| Premium Revenue (Note 5) 13,115,132 - 0. TOTAL OPERATING REVENUES 827,304,296 752,408,296 9. EXPENSE Salaries and Wages 312,644,464 288,663,876 -8. Fringe Benefits 116,207,559 103,254,398 -12. Purchased Personnel 7,709,285 5,703,203 -35. Medical Claims Expense (Note 5) 8,014,040 100. Supplies 159,492,887 139,658,006 -14. Other Operating Expense 149,372,302 136,140,867 -9. Interest Expense 5,228,688 5,256,206 0. Depreciation/Amortization 51,920,053 45,969,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME 19,930,2241 9,681,971 -3. Investment Income (Note 3) 15,192,251 1,169,368 1199. Joint Venture Income (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) 9,890,2241 9,681,971 -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13. Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35. | | | , | | 7.49% |
| Premium Revenue (Note 5) 13,115,132 - 0. TOTAL OPERATING REVENUES 827,304,296 752,408,296 9. EXPENSE Salaries and Wages 312,644,464 288,663,876 -8. Fringe Benefits 116,207,559 103,254,398 -12. Purchased Personnel 7,709,285 5,703,203 -35. Medical Claims Expense (Note 5) 8,014,040 100. Supplies 159,492,887 139,658,006 -14. Other Operating Expense 149,372,302 136,140,867 -9. Interest Expense 51,228,688 5,256,206 0. Depreciation/Amortization 51,920,053 45,969,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME 15,192,251 1,169,368 1199. Joint Venture Income (Note 3) 15,192,251 1,169,368 1199. Joint Venture Income (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,881,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13. Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35. | Other Operation Develope | | 22 204 675 | 25 022 400 | 20.200/ |
| EXPENSE Salaries and Wages S12,644,464 288,663,876 -8. Fringe Benefits 116,207,559 103,254,398 -12. Purchased Personnel 7,709,285 5,703,203 -35. Medical Claims Expense (Note 5) 8,014,040 - -100. Supplies 159,492,887 139,658,006 -14. Other Operating Expense 149,372,302 136,140,867 -9. Interest Expense 5,228,688 5,256,206 0. Other Operating Expense 5,1920,053 45,969,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME Investment Income (Note 3) 15,192,251 1,169,368 1199. Joint Venture Income (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,881,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13. Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | | | | 25,922,499 | 28.39% |
| Salaries and Wages 312,644,464 288,663,876 -8. | | | | 752 400 206 | 0.00% |
| Salaries and Wages 312,644,464 288,663,876 -8. Fringe Benefits 116,207,559 103,254,398 -12. Purchased Personnel 7,709,285 5,703,203 -35. Medical Claims Expense (Note 5) 8,014,040 - -100. Supplies 159,492,887 139,658,006 -14. Other Operating Expense 149,372,302 136,140,867 -9. Interest Expense 5,228,688 5,256,206 0. Depreciation/Amortization 51,920,053 45,969,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME 1nvestment Income (Note 3) 15,192,251 1,169,368 1199. Joint Venture Income (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 < | TOTAL OPERATING REVENUES | | 827,304,296 | 752,408,296 | 9.95% |
| Fringe Benefits | | | | | |
| Purchased Personnel | | | | | -8.31% |
| Medical Claims Expense (Note 5) | Fringe Benefits | | | | -12.54% |
| Supplies | Purchased Personnel | | 7,709,285 | 5,703,203 | -35.17% |
| Other Operating Expense Interest Expense 149,372,302 136,140,867 -9. Interest Expense Depreciation/Amortization 51,226,688 5,226,608 0. Depreciation/Amortization 51,920,053 45,989,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME Investment Income (Note 3) Joint Venture Income (Note 4) 15,192,251 1,169,368 1199. Other Expenses, Net (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | Medical Claims Expense (Note 5) | | 8,014,040 | - | -100.00% |
| Other Operating Expense Interest Expense 149,372,302 136,140,867 -9. Interest Expense Depreciation/Amortization 51,226,688 5,226,608 0. Depreciation/Amortization 51,920,053 45,989,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME Investment Income (Note 3) Joint Venture Income (Note 4) 15,192,251 1,169,368 1199. Other Expenses, Net (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | Supplies | | 159,492,887 | 139,658,006 | -14.20% |
| Interest Expense 5,228,688 5,256,206 0. Depreciation/Amortization 51,920,053 45,969,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME | | | | 136.140.867 | -9.72% |
| Depreciation/Amortization 51,920,053 45,969,564 -12. TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME | | | | | 0.52% |
| TOTAL OPERATING EXPENSE 810,589,278 724,646,120 -11. INCOME FROM OPERATIONS (Note 6) 16,715,018 27,762,176 -39. OTHER INCOME Investment Income (Note 3) 15,192,251 1,169,368 1199. Joint Venture Income (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | | | | | -12.94% |
| OTHER INCOME Investment Income (Note 3) 15,192,251 1,169,368 1199. Joint Venture Income (Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | · | | | | -11.86% |
| Investment Income (Note 3) 15,192,251 1,169,368 1199. Joint Venture Income(Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13. Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35. | INCOME FROM OPERATIONS (Note 6) | | 16,715,018 | 27,762,176 | -39.79% |
| Investment Income (Note 3) | OTHER INCOME | | | | |
| Joint Venture Income(Note 4) 2,576,605 2,137,506 20. Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13. Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35. | • ***-** | | 15 102 251 | 1 160 260 | 1100 100/ |
| Other Expenses, Net (Note 4) (9,980,224) (9,681,971) -3. Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | | | | | 1199.18% |
| Total Other Income (Note 6) 7,788,632 (6,375,097) -222. EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | | | | | 20.54% |
| EXCESS OF REVENUES OVER EXPENSE BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | | | | | -3.08% |
| BEFORE MINORITY INTEREST (Note 6) 24,503,650 21,387,079 14. Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | Total Other Income (Note 6) | - | 7,788,632 | (6,375,097) | -222.17% |
| Minority Interest Expense (Income) 357,357 121,873 193. EXCESS OF REVENUES OVER EXPENSE (Note 6) 24,146,293 21,265,206 13 Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | EXCESS OF REVENUES OVER EXPENSE | | | | |
| EXCESS OF REVENUES OVER EXPENSE (Note 6) Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | BEFORE MINORITY INTEREST (Note 6) | | 24,503,650 | 21,387,079 | 14.57% |
| Change In Net Unrealized Gains and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | Minority Interest Expense (Income) | | 357,357 | 121,873 | 193.22% |
| and Losses on Investments (Note 3) (12,413,200) (337,699) -35 | EXCESS OF REVENUES OVER EXPENSE (Note 6) | | 24,146,293 | 21,265,206 | 13.5% |
| | | | (12,413,200) | (337,699) | -3576% |
| INCREASE IN UNRESTRICTED NET ASSETS \$ 11 733 093 20 927 507 -43 | INCREASE IN UNRESTRICTED NET ASSETS | \$ | 11,733,093 | 20,927,507 | -43.93% |

Cone Health Consolidated Statement of Changes in Net Assets

| | | Audited |
|--|----------------|--------------------|
| | March 31, 2016 | September 30, 2015 |
| UNRESTRICTED NET ASSETS: | | |
| Excess of revenues over expenses from consolidated operations | \$24,503,650 | \$44,561,749 |
| Change in net unrealized gains and losses on investments | (\$8,500,150) | (50,676,708) |
| Change in the fair value of the floating-to-fixed swap agreement | (\$3,913,050) | (7,169,160) |
| Other changes in net assets | (\$1,180,077) | (15,214,314) |
| Increase in unrestricted net assets | 10,910,373 | (28,498,433) |
| TEMPORARILY RESTRICTED NET ASSETS: | | |
| Other changes in net assets | (720,849) | 1,442,946 |
| Increase in temporarily restricted net assets | (720,849) | 1,442,946 |
| INCREASE IN NET ASSETS | \$10,189,524 | (\$27,055,487) |

Cone Health Consolidated Statements of Cash Flows

| | ı | March 31, 2016 | Sep | tember 30, 2015 |
|---|----|----------------|-----|-----------------|
| CASH FLOWS FROM OPERATING AND NON OPERATING ACTIVITIES | | | | |
| CASH PROVIDED BY OPERATING ACTIVITIES | | | | |
| Increase (Decrease) in net assets | \$ | 10,189,524 | \$ | (27,055,487) |
| Adjustments to reconcile revenue and gains in excess of expenses and losses to | | | | |
| net cash provided by operating activities: | | 0.500.450 | | 50.070.700 |
| Change in net unrealized gains and losses on investments | | 8,500,150 | | 50,676,708 |
| Change in fair value of the floating-to-fixed swap agreement | | 3,913,050 | | 7,169,160 |
| Inherent contribution from the acquisition of ARMC Net realized gains on sale of investments | | (7,799,523) | | (2,347,044) |
| Depreciation and amortization | | 51,920,154 | | 94,524,608 |
| Provision for uncollectible accounts | | 66,956,006 | | 122,020,320 |
| Accumulated or Other Comprehensive Income (FAS 158) | | - | | 9,660,933 |
| Funding in excess of net periodic pension cost | | _ | | (4,582,492) |
| Gain on disposal of property and equipment | | 33,138 | | 816,592 |
| Equity in earnings of unconsolidated entities | | (2,576,605) | | (5,894,089) |
| Distributions from unconsolidated affiliates | | 1,043,958 | | 1,284,826 |
| Changes to Medical Claims IBNR in Care-n-Care of NC | | (3,215,649) | | - |
| (Increase) Decrease in patient accounts receivable | | (80,458,734) | | (138,592,279) |
| (Increase) Decrease in other current assets | | (21,327,155) | | 27,536,254 |
| (Increase) Decrease in inventory | | (1,345,443) | | (965,026) |
| Increase (Decrease) in accounts payable and accrued expenses | | (748,983) | | 6,354,944 |
| Change in other operating assets and liabilities, net | | (3,512,793) | | 18,350,681 |
| Net cash provided by operating activities and gains and losses | \$ | 21,571,094 | \$ | 158,958,610 |
| CASH FLOWS FROM INVESTING ACTIVITY | | | | |
| Additions to Property, Plant and Equipment | | (58,524,632) | | (108,630,944) |
| Proceeds from sale of poperty and equipmet | | 11,499 | | 196,312 |
| Liquidation of trusted funds for capital expenditures | | - | | 8,757,091 |
| (Increase)/decrease in investment portfolios | | 39,091,018 | | (62,509,633) |
| Acquisiton of physician practice | | , , , <u>-</u> | | (829,186) |
| Investments in unconsolidated affiliated entities | | 789,284 | | (452,912) |
| Net cash used in investing activities | | (18,632,831) | | (163,469,272) |
| | | | | |
| CASH FLOWS FROM FINANCING ACTIVITY | | 0.4.000.400 | | |
| Proceeds from debt issuances | | 34,260,489 | | (40 550 440) |
| Repayments of debt | | (11,750,366) | | (12,558,149) |
| Restriction of cash for debt service | | - | | - |
| Repayments of deferred costs Borrowings on capital lease obligations | | | | |
| Payments on capital lease obligations | | (867,041) | | (1,596,197) |
| rayments on capital lease obligations | | (867,041) | | (1,590,197) |
| Net cash provided by (used in) financing activities | | 21,643,082 | | (14,154,346) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | | 24,581,345 | | (18,665,009) |
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | | 27,152,128 | | 45,817,137 |
| CASH AND CASH EQUIVALENTS, END OF PERIOD | \$ | 51,733,473 | \$ | 27,152,128 |